Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

NCT02709083 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT02709083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02709083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2016
Completion date
July 31, 2018
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia, chronic myeloid leukemia, leukemia